Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Venetoclax and Relapsed/Refractory Chronic Lymphocytic Lymphoma

DECEMBER 11, 2016
Jeffrey Jones, MD, MPH



Jeffrey Jones, MD, MPH of Ohio State University talks about the safety and efficacy of venetoclax monotherapy in patients with relapsed or refractory CLL.

Reference

Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Presented at 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016


Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.